Published in Am J Epidemiol on August 02, 2005
Overutilization of endoscopic surveillance in nondysplastic Barrett's esophagus: a multicenter study. Gastrointest Endosc (2011) 1.82
Sex and race and/or ethnicity differences in patients undergoing radiofrequency ablation for Barrett's esophagus: results from the U.S. RFA Registry. Gastrointest Endosc (2015) 1.45
Single nucleotide polymorphisms of caudal type homeobox 1 and 2 are associated with Barrett's esophagus. Dig Dis Sci (2013) 1.42
Alcohol types and sociodemographic characteristics as risk factors for Barrett's esophagus. Gastroenterology (2008) 1.19
BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am J Gastroenterol (2015) 1.17
Prevalence of complicated gastroesophageal reflux disease and Barrett's esophagus among racial groups in a multi-center consortium. Dig Dis Sci (2009) 1.16
Risk factors for Barrett's esophagus among patients with gastroesophageal reflux disease: a community clinic-based case-control study. Am J Gastroenterol (2009) 1.14
Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol (2012) 1.09
The natural course of Helicobacter pylori infection on endoscopic findings in a population during 17 years of follow-up: the Sørreisa gastrointestinal disorder study. Eur J Epidemiol (2009) 0.96
Natural history of Barrett's esophagus. World J Gastroenterol (2012) 0.93
Current status and future perspectives on the etiology of esophageal adenocarcinoma. Front Oncol (2012) 0.89
Gallstones increase the prevalence of Barrett's esophagus. J Gastroenterol (2009) 0.88
Sex and Gender Differences in Gastroesophageal Reflux Disease. J Neurogastroenterol Motil (2016) 0.87
Ethnicity in relation to incidence of oesophageal and gastric cancer in England. Br J Cancer (2012) 0.84
Gastro-esophageal reflux disease symptoms and demographic factors as a pre-screening tool for Barrett's esophagus. PLoS One (2014) 0.83
Prevalence of overweightedness in patients with gastro-esophageal reflux. World J Gastroenterol (2007) 0.81
Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterol Clin North Am (2015) 0.79
The value of traditional upper endoscopy as a diagnostic test for Barrett's esophagus. Gastrointest Endosc (2008) 0.79
Effect of body weight and esophageal damage on the severity of gastroesophageal reflux symptoms. Mexican GERD working group. Arch Med Res (2009) 0.78
Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis. Osteoporos Int (2016) 0.78
The Prevalence, Risk Factors, and Clinical Correlates of Erosive Esophagitis and Barrett's Esophagus in Iranian Patients with Reflux Symptoms. Gastroenterol Res Pract (2014) 0.77
Barrett's esophagus in 2016: From pathophysiology to treatment. World J Gastrointest Pharmacol Ther (2016) 0.76
Gender differences, aging and hormonal status in mucosal injury and repair. Aging Dis (2014) 0.76
Gender difference in gastro-esophageal reflux diseases. World J Gastroenterol (2016) 0.76
MIC-1/GDF15 in Barrett's oesophagus and oesophageal adenocarcinoma. Br J Cancer (2015) 0.76
Progression from low-grade dysplasia to malignancy in patients with Barrett's esophagus diagnosed by two or more pathologists. World J Gastroenterol (2016) 0.75
Ischemic heart disease, factor predisposing to Barrett's adenocarcinoma: A case control study. World J Gastrointest Pharmacol Ther (2014) 0.75
Association between gastroesophageal reflux disease and coronary heart disease: A nationwide population-based analysis. Medicine (Baltimore) (2016) 0.75
Update on management of Barrett's esophagus. World J Gastrointest Pharmacol Ther (2016) 0.75
The frequency of histologically confirmed Barrett's esophagus varies by the combination of ethnicity and gender. J Gastrointest Oncol (2017) 0.75
Prevalence and Epidemiological Characteristics of Endoscopically Proven Reflux Esophagitis in Children in Korea. Pediatr Gastroenterol Hepatol Nutr (2017) 0.75
The Genetics of Barrett's Esophagus: A Familial and Population-Based Perspective. Dig Dis Sci (2016) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2014) 40.30
Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol (2012) 9.28
Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol (2012) 6.37
Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet (2012) 4.76
Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncol (2009) 4.44
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut (2013) 4.29
Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol (2007) 4.14
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ (2008) 4.12
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 3.97
Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology (2010) 3.32
Thirty-day postoperative mortality after colorectal cancer surgery in England. Gut (2011) 3.07
Effect of comorbidity on mortality in patients with peptic ulcer bleeding: systematic review and meta-analysis. Am J Gastroenterol (2013) 2.97
Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA (2008) 2.89
An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol (2003) 2.83
A systematic review and meta-analysis of the risk of increasing adiposity on Barrett's esophagus. Am J Gastroenterol (2007) 2.79
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology (2004) 2.59
Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol (2005) 2.56
Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev (2013) 2.53
Management of Barrett's esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. Am J Gastroenterol (2008) 2.52
Cancer burden in Africa and opportunities for prevention. Cancer (2012) 2.51
Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev (2010) 2.47
Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology (2006) 2.46
American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology (2005) 2.39
Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol (2005) 2.36
The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet (2005) 2.26
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet (2006) 2.23
Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut (2010) 2.21
Fifty years of cancer incidence: CI5 I-IX. Int J Cancer (2010) 2.14
Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology (2013) 2.13
The role of hemochromatosis susceptibility gene mutations in protecting against iron deficiency in celiac disease. Gastroenterology (2002) 2.12
Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology (2005) 2.07
Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 2.04
Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol (2008) 2.02
Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med (2013) 2.01
Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol (2007) 2.00
A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis (2002) 1.89
EUS: a meta-analysis of test performance in suspected choledocholithiasis. Gastrointest Endosc (2008) 1.85
Ulcerative colitis. BMJ (2013) 1.76
Do testicular seminoma and nonseminoma share the same etiology? Evidence from an age-period-cohort analysis of incidence trends in eight European countries. Cancer Epidemiol Biomarkers Prev (2006) 1.75
Gastric cancer: epidemiology and risk factors. Gastroenterol Clin North Am (2013) 1.74
Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol (2009) 1.67
Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.60
Symptom-based outcome measures for dyspepsia and GERD trials: a systematic review. Am J Gastroenterol (2005) 1.59
Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study. Gastroenterology (2010) 1.58
Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev (2015) 1.58
Dyspeptic symptoms and endoscopic findings in the community: the Loiano-Monghidoro study. Am J Gastroenterol (2009) 1.58
Helicobacter pylori infection and gastric cancer--for want of more outcomes. JAMA (2004) 1.57
Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev (2007) 1.57
Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer (2003) 1.55
Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst (2004) 1.54
Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med (2009) 1.53
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer (2014) 1.50
5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol (2010) 1.50
Inconsistent definitions for intention-to-treat in relation to missing outcome data: systematic review of the methods literature. PLoS One (2012) 1.48
Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology. Gut (2007) 1.47
Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol (2004) 1.47
Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol (2008) 1.44
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol (2011) 1.42
Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol (2013) 1.41
Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol (2005) 1.40
Acid-suppressive therapy with esomeprazole for relief of unexplained chest pain in primary care: a randomized, double-blind, placebo-controlled trial. Am J Gastroenterol (2012) 1.40
Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol (2009) 1.39
Relation of adult lifestyle and socioeconomic factors to the prevalence of Helicobacter pylori infection. Int J Epidemiol (2002) 1.39
Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology (2002) 1.36
Polymorphisms in inflammatory response genes and their association with gastric cancer: A HuGE systematic review and meta-analyses. Am J Epidemiol (2010) 1.35
Primary health and supportive care needs of long-term cancer survivors: a questionnaire survey. J Clin Oncol (2011) 1.29
Risk of mortality and cancer incidence in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev (2007) 1.29
Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol (2009) 1.29
Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 1.24
Interventions for dysphagia in oesophageal cancer. Cochrane Database Syst Rev (2009) 1.22
Are there socioeconomic gradients in stage and grade of breast cancer at diagnosis? Cross sectional analysis of UK cancer registry data. BMJ (2004) 1.22
A systematic review and meta-analysis of perinatal variables in relation to the risk of testicular cancer--experiences of the son. Int J Epidemiol (2010) 1.19
Vegetable, fruit and meat consumption and potential risk modifying genes in relation to colorectal cancer. Int J Cancer (2004) 1.18
Canadian Helicobacter Study Group Consensus Conference: Update on the approach to Helicobacter pylori infection in children and adolescents--an evidence-based evaluation. Can J Gastroenterol (2005) 1.17
No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma. Pharmacogenet Genomics (2005) 1.16
Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol (2009) 1.16
Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.14
Joint disease mapping using six cancers in the Yorkshire region of England. Int J Health Geogr (2008) 1.14
Ten-year survival and risk of relapse for testicular cancer: a EUROCARE high resolution study. Eur J Cancer (2007) 1.13
Are there socioeconomic gradients in the quality of data held by UK cancer registries? J Epidemiol Community Health (2004) 1.13
How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol (2003) 1.12
The burden of stomach cancer in indigenous populations: a systematic review and global assessment. Gut (2013) 1.11
Who consults with dyspepsia? Results from a longitudinal 10-yr follow-up study. Am J Gastroenterol (2007) 1.11
Functional Dyspepsia Treatment Trial (FDTT): a double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics. Contemp Clin Trials (2012) 1.10
Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.10
What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol (2010) 1.10
An international comparison of male and female breast cancer incidence rates. Int J Cancer (2012) 1.09
Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study. Gut (2006) 1.08